Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagenic Therapeutics Inc (NQ: PTIX )

0.6360 UNCHANGED
Streaming Delayed Price Updated: 3:55 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,470
Open 0.6360
Bid (Size) 0.5836 (1)
Ask (Size) 0.6122 (2)
Prev. Close 0.6360
Today's Range 0.5799 - 0.6360
52wk Range 0.5000 - 1.870
Shares Outstanding 4,467,266
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-30.87%
-30.87%
1 Month
+5.65%
+5.65%
3 Month
-25.44%
-25.44%
6 Month
-60.50%
-60.50%
1 Year
-42.18%
-42.18%

More News

Read More
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
Via ACCESSWIRE
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Via ACCESSWIRE
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024
Via InvestorPlace
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
Via ACCESSWIRE
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Via ACCESSWIRE
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Via ACCESSWIRE
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Via ACCESSWIRE
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Via ACCESSWIRE
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
Via InvestorPlace
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Via ACCESSWIRE
Earnings Scheduled For April 1, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.